Information Provided By: 
Fly News Breaks for February 14, 2017
GSK, GILD
Feb 14, 2017 | 07:32 EDT
RBC Capital analyst Michael Yee says that data on Gilead's (GILD) HIV treatment, bictegravir, shows that the drug was more effective than GlaxoSmithKline's (GSK) dolutegravir in treatment-naive HIV patients. The analyst thinks that the data indicates that Gilead's HIV franchise should be valued at $50+ per share, although he warns that data on a GlaxoSmithKline treatment due to next year could pose a threat to Gilead. He keeps an Outperform rating on Gilead.
News For GILD;GSK From the Last 2 Days
GSK
Apr 24, 2024 | 06:25 EDT
GSK
Apr 23, 2024 | 08:34 EDT
GILD
Apr 22, 2024 | 07:19 EDT
Cantor Fitzgerald lowered the firm's price target on Gilead to $75 from $78 and keeps a Neutral rating on the shares. The firm, which made slight adjustments to all of its large-cap biotechnology models ahead of Q1 earnings season for the group, lowered its target for Gilead given slower expected HIV growth. The "usual seasonal headwinds that typically make this one of the weaker quarters for the industry," the analyst added in the preview note.
